|
|
| (5 intermediate revisions by 3 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Metoprolol succinate#Pharmacology]] |
| {{Metoprolol}}
| |
| {{CMG}}
| |
| | |
| ====Mechanism of Action====
| |
| | |
| '''Hypertension''': The mechanism of the antihypertensive effects of [[beta-blocking agent]]s has not been elucidated. However, several possible mechanisms have been proposed: (1) competitive [[antagonism]] of [[catecholamine]]s at peripheral (especially cardiac) adrenergic neuron sites, leading to decreased [[cardiac output]]; (2) a central effect leading to reduced sympathetic outflow to the periphery; and (3) suppression of [[renin]] activity.
| |
| | |
| '''Heart Failure''': The precise mechanism for the beneficial effects of [[beta-blocker]]s in [[heart failure]] has not been elucidated.
| |
| | |
| ====Pharmacodynamics====
| |
| | |
| Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in [[heart rate]] and [[cardiac output]] at rest and upon exercise, (2) reduction of [[systolic blood pressure]] upon [[exercise]], (3) inhibition of [[isoproterenol]]-induced [[tachycardia]], and (4) reduction of reflex orthostatic [[tachycardia]].
| |
| | |
| Metoprolol is a [[beta1]]-selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits [[beta2]]-adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no [[intrinsic sympathomimetic activity]], and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade. Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.
| |
| | |
| The relative [[beta1]]-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the [[beta2]]-mediated [[vasodilation|vasodilating]] effects of [[epinephrine]]. This contrasts with the effect of nonselective [[beta-blocker]]s, which completely reverse the [[vasodilation|vasodilating]] effects of [[epinephrine]]. (2) In [[asthmatic]] patients, metoprolol reduces [[FEV1]] and [[FVC]] significantly less than a nonselective beta-blocker, [[propranolol]], at equivalent [[beta1]]-receptor blocking doses.
| |
| | |
| The relationship between plasma metoprolol levels and reduction in exercise heart rate is independent of the pharmaceutical formulation. Using an Emax model, the maximum effect is a 30% reduction in exercise [[heart rate]], which is attributed to [[beta1]]-blockade. [[Beta1]]-blocking effects in the range of 30-80% of the maximal effect (approximately 8-23% reduction in exercise heart rate) correspond to metoprolol plasma concentrations from 30-540 nmol/L. The relative [[beta1]]-selectivity of metoprolol diminishes and blockade of [[beta2]]-adrenoceptors increases at plasma concentration above 300 nmol/L.
| |
| | |
| Although beta-adrenergic receptor blockade is useful in the treatment of [[angina]], [[hypertension]], and [[heart failure]] there are situations in which sympathetic stimulation is vital. In patients with severely damaged hearts, adequate ventricular function may depend on sympathetic drive. In the presence of [[AV block]], [[beta-blockade]] may prevent the necessary facilitating effect of [[sympathetic]] activity on conduction. [[Beta2]]-adrenergic blockade results in passive bronchial constriction by interfering with endogenous adrenergic [[bronchodilation|bronchodilator]] activity in patients subject to [[bronchospasm]] and may also interfere with exogenous [[bronchodilation|bronchodilators]] in such patients.
| |
| | |
| In other studies, treatment with TOPROL-XL produced an improvement in left ventricular [[ejection fraction]]. TOPROL-XL was also shown to delay the increase in left ventricular end-systolic and end-diastolic volumes after 6 months of treatment.
| |
| | |
| ====Pharmacokinetics====
| |
| | |
| '''Adults''': In man, absorption of metoprolol is rapid and complete. Plasma levels following oral administration of conventional metoprolol tablets, however, approximate 50% of levels following intravenous administration, indicating about 50% [[first-pass metabolism]]. Metoprolol crosses the [[blood-brain barrier]] and has been reported in the [[CSF]] in a concentration 78% of the simultaneous plasma concentration.
| |
| | |
| Plasma levels achieved are highly variable after oral administration. Only a small fraction of the drug (about 12%) is bound to human serum [[albumin]]. Metoprolol is a racemic mixture of R- and S- enantiomers, and is primarily metabolized by [[CYP2D6]]. When administered orally, it exhibits stereoselective metabolism that is dependent on oxidation phenotype.
| |
| | |
| Elimination is mainly by biotransformation in the liver, and the plasma half-life ranges from approximately 3 to 7 hours. Less than 5% of an oral dose of metoprolol is recovered unchanged in the urine; the rest is excreted by the kidneys as metabolites that appear to have no beta-blocking activity.
| |
| | |
| Following intravenous administration of metoprolol, the urinary recovery of unchanged drug is approximately 10%. The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects. Consequently, no reduction in metoprolol succinate dosage is usually needed in patients with chronic renal failure.
| |
| | |
| Metoprolol is metabolized predominantly by CYP2D6, an enzyme that is absent in about 8% of Caucasians (poor metabolizers) and about 2% of most other populations. CYP2D6 can be inhibited by a number of drugs. Poor metabolizers and extensive metabolizers who concomitantly use CYP2D6 inhibiting drugs will have increased (several-fold) metoprolol blood levels, decreasing metoprolol's cardioselectivity [see Drug Interactions (7.2)].
| |
| | |
| In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation. The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses. At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol. Nevertheless, over the 24-hour dosing interval, β1-blockade is comparable and dose-related [see Clinical Pharmacology (12)]. The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.
| |
| | |
| Pediatrics: The pharmacokinetic profile of TOPROL-XL was studied in 120 pediatric hypertensive patients (6-17 years of age) receiving doses ranging from 12.5 to 200 mg once daily. The pharmacokinetics of metoprolol were similar to those described previously in adults. Age, gender, race, and ideal body weight had no significant effects on metoprolol pharmacokinetics. Metoprolol apparent oral clearance (CL/F) increased linearly with body weight. Metoprolol pharmacokinetics have not been investigated in patients < 6 years of age.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TOPROL XL (METOPROLOL SUCCINATE) TABLET, EXTENDED RELEASE [BRYANT RANCH PREPACK] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=01038198-b4f0-41f3-9a9c-5c84e5a0d3b9 | publisher = | date = | accessdate = }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist}}
| |
| | |
| {{FDA}}
| |
| | |
| [[Category:Beta blockers]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |